Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Johnson & Johnson’s medtech leader said Wednesday that the company is now working with the Food and Drug Administration about safety risks tied to its Varipulse pulsed field ablation device.

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson (J&J) MedTech has reported a 4.8% growth in global sales in 2024, though it expects its 2025 outlook to ...

Amy Paterson, Medical Analyst at GlobalData states, “Medtronic’s Sphere-9 launched at a lower price than Boston Scientific’s ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Major highlights of the year include the approval of our VARIPULSE Pulsed Field Ablation platform in several major markets and FDA clearance of our VELYS robotic assisted solution for the use in ...

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson ...

But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...